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Abstract
Neuroferritinopathy or hereditary ferritinopathy is an inherited neurodegenerative disease caused
by mutations in ferritin light chain (FTL) gene. The clinical features of the disease are highly
variable, and include a movement disorder, behavioral abnormalities, and cognitive impairment.
Neuropathologically, the disease is characterized by abnormal iron and ferritin deposition in the
central nervous system. We report a family in which neuroferritinopathy begins with chronic
headaches, later developing progressive orolingual and arm dystonia, dysarthria, cerebellar ataxia,
pyramidal tract signs, and psychiatric symptoms. In the absence of classic clinical symptoms, the
initial diagnosis of the disease was based on magnetic resonance imaging studies. Biochemical
studies on the proband showed normal serum ferritin levels, but remarkably low cerebrospinal
fluid (CSF) ferritin levels. A novel FTL mutation was identified in the proband. Our findings
expand the genetic and clinical diversity of neuroferritinopathy and suggest CSF ferritin levels as
a novel potential biochemical marker for the diagnosis of neuroferritinopathy.
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1. INTRODUCTION
Neuroferritinopathy or hereditary ferritinopathy (Muhoberac, 2013) is an autosomal
dominant movement disorder caused by mutations in the ferritin light chain gene (FTL) on
chromosome 19q13.3. Neuropathologically, the disease is characterized by the abnormal
depositions of iron and ferritin in the brain, particularly in the basal ganglia. Thus far, six
different mutations in exon four of the FTL gene have been reported, all affecting the FTL
polypeptide C-terminus (Curtis, 2001; Vidal, 2004; Mancuso, 2005; Ohta, 2008; Devos,
2009; Kubota, 2009). Clinically, the disease presents as a middle-age–onset chorea and
dystonia. Clinical presentation may also include extrapyramidal and pyramidal tract signs as
well as cerebellar ataxia, dysautonomia, cognitive decline, and psychiatric symptoms;
however, the clinical presentation is highly variable both within and between families
(Wills, 2002; Chinnery, 2003; Mir, 2005; Chinnery, 2007; Cassidy, 2011; Crompton, 2005;
Ory-Magne, 2009). Several in vitro and in vivo studies (reviewed in Muhoberac, 2013) have
implicated at least two key toxic mechanisms in the pathogenesis of the disease: abnormal
iron metabolism and generation of free radicals, and abnormal ferritin aggregation. These
two mechanisms may be acting together to lead to neurodegeneration and thus to the
progression of the disease. The mutant FTL polypeptide can cause deregulation of cellular
iron metabolism (ferritin loss of function), oxidative stress, and overproduction of ferritin
polypeptides (a positive feedback loop), while excess iron and ferritin could trigger the
formation of ferritin aggregates, which may physically interfere with normal cellular
functions (gain of a toxic function) (Vidal, 2011).
Herein, we report the identification of a novel mutation in the FTL gene in a Japanese family
with neuroferritinopathy, and highlight the utility of T2-weighted magnetic resonance
imaging and biochemical studies as potential biomarkers for the diagnosis of the disease.
2. SUBJECTS AND METHODS
2.1. Case Report
The proband, a 44-year-old, right-handed Japanese female, presented initially with chronic
headaches at the age of 42. She was allergic to milk, wheat, and eggs. There was no history
of anoxia at birth or carbon monoxide poisoning and no family history of neurodegenerative
disorders or consanguineous marriage (Fig. 1A). At the age of 43, she demonstrated
psychiatric disturbances such as emotional lability, and was diagnosed with panic disorder at
a mental health clinic. At the age of 44, she experienced difficulty in speaking and walking
as well as clumsiness in her left arm. Neurological examination showed emotional
incontinence, mild cognitive decline (Full scale Intelligence Quotient = 83, Verbal
Intelligence Quotient = 84, Performance Intelligence Quotient = 84), slurred speech,
bilateral hyperextensibility and hypotonus, left-sided cerebellar ataxia, hyperreflexia, and
extensor plantar response. Cranial nerve examination showed slow eye saccades and
involuntary movement of tongue. Rigidity, spasticity, tremor, dystonia, chorea, and
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parkinsonism were not observed initially. Her gait was unsteady (not wide-based); she
exhibited some difficulty during tandem gait. Gait disturbance gradually progressed, and her
gait became increasingly unsteady with a tendency to fall. Limb weakness, sensory
disturbance, and bladder or rectal disturbances were not observed. Orthostatic hypotension
was detected by the head-up tilt test (blood pressure: 121/79 mmHg in the supine, 90/63
mmHg in the standing position with dizziness). Several months after the initial presentation,
oromandibular, orolingual, and left dominant arm dystonia, tongue dyskinesia, tongue
wiggling movements, tongue biting, and dysphagia developed. Her serum ferritin levels
were 20 ng/mL (normal range, 5–204 ng/mL). Serum levels of iron, copper, ceruloplasmin,
hemoglobin, and vitamin E were normal. Routine hematological studies and thyroid function
studies were also normal. No tumor markers or autoimmune antibodies such as anti-glutamic
acid decarboxylase and anti-gliadin were detected. An abdominal computed tomography
(CT)/MRI showed the presence of a left ovarian cyst; however, tests for paraneoplastic
antibodies such as anti-Hu and anti-Yo in serum and CSF were negative. Analysis of CSF
revealed a remarkably low ferritin level (<1.00 ng/mL, normal range 6.68 ± 0.93 ng/mL).
Several medications, including trihexyphenidyl, benzodiazepine, valproate, and muscle
relaxants, were attempted; however, they did not improve the patient’s symptoms. Herbal
medicine (Shakuyaku-kanzo-to) relieved the left finger hyperextensibility due to dystonia.
2.2. Methods
MRI, laboratory tests including measurement of serum ferritin levels and genetic analysis
were performed on the proband and her family (parents and brother). CSF ferritin levels
were also measured on the proband. Brain MRI was performed using a 1.5-Tesla system
(GyroscanAchieva; Philips Medical Systems, Best, The Netherlands). T1-weighted (TR =
600 ms, TE = 12 mc), T2-weighted (TR = 4423 ms, TE = 100 ms), and T2*-weighted (TR =
640 ms, TE = 23 ms) sequences were acquired in the transverse plane. In the proband,
susceptibility-weighted imaging (SWI) based on 3-dimensional T1-weighted fast field echo
(3DT1FFE) and 123I-iodoamphetamine (IMP) single photon emission tomography (IMP-
SPECT) were also performed.
After informed consent was obtained, genomic DNA was extracted from a 500 μl saliva
aliquot collected with the Oragene Discover Collection Kit (DNAgenotek, Ottawa, Canada)
using prepIT-C2D Genomic DNA MiniPrep Kit (Oragene) in accordance with the
manufacturer’s instructions. PCR amplification was performed on 0.15 ug of genomic DNA
to amplify all four exons of the FTL gene using the oligonucleotide primer pairs: Exon
1(352bp) F: 5′-ACGTCCCCTCGCAGTTCGGCGG-3′ and R: 5′-
GGAGGTGCGCAGCTGGAGG-3′; Exon 2(327bp)F: 5′-
GGTAAACAGAGGGCGGAGTC-3′ and R: 5′-ACCGAACTCAATCTCCCAGA-3′; and
Exon 3 & 4(660 bp) F: 5′-TGTAGGTTTAGTTCTATGTG-3′ and R: 5′-
AAGCCCTATTACTTTGCAAG-3′; at 2 mmol each oligonucleotide, 200 μmol dNTPs, and
1.5 mM MgCl2 in a 50 μl reaction, and cycled for 35 cycles of 94°C for 30 s, 45°C for 45 s,
and 72°C for 45 s. DNA fragments were separated on a 1% agarose gel, visualized by
ethidium bromide staining, and the corresponding bands excised and purified using the
GeneJET Gel Extraction Kit (Thermo Scientific, Lithuania). DNA sequencing was
performed in both directions as described (Vidal, 2004) using a CEQ 8000 GeXP Genetic
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Analysis System and Software (Beckman Coulter). Amplification products of exons 3 and 4
were also subcloned into pCR 2.1 vector (Invitrogen, Carlsbad, CA) and transformed into
One Shot® TOP10 Chemically Competent E. coli cells (Invitrogen) according to the
manufacturer’s protocol. Recombinant plasmid DNA was isolated from 10 clones of
different PCR reactions and sequenced in both directions as described (Vidal, 2004).
3. RESULTS
3.1. Imagining Studies
Brain MRI of the proband showed symmetrical hyperintense areas surrounded by
hypointense areas in the bilateral posterior globus pallidus and putamen at age 42 (Fig. 1B).
At age 43, Brain CT revealed symmetrical low density areas in the bilateral basal ganglia
(Fig. 2A). T1-wighted MRI images demonstrated cortical atrophy of the cerebrum and
cerebellum. T2-weighted MRI revealed symmetrical hyperintense areas surrounded by
hypointense areas in the bilateral posterior globus pallidus and putamen, whereas T2*-
weighted and SWI-MRI revealed hypointense areas in the globus pallidus, putamen,
thalamus, red nucleus, dentate nucleus, and cerebral cortex (Fig. 2 and 3). No spinal cord
lesions were observed. 123I-iodoamphetamine single photon emission tomography (IMP-
SPECT) revealed bilateral mild hypoperfusion of the cerebellum and right hypoperfusion of
the basal ganglia (Fig. 4). Cardiac 123I-metaiodobenzylguanidine (MIBG) uptake was not
decreased (H/M ratios for early phase 2.70 and delayed phase 2.78).
3.2 Ferritin measurements
Serum ferritin values in the proband, her parents and brother were in the normal range (5–
204 ng/mL). CSF ferritin levels in the proband were remarkably low (<1.00 ng/mL, normal
range 6.68 ± 0.93 ng/mL).
3.3. Genetic Analysis
The sequence of exons 1, 2 and 3 of the FTL gene and adjacent intronic sequences were
found to be normal. Gel migration analysis of a PCR product comprising exons 3 and 4 of
FTL revealed the presence of two amplification products of 660 and 676 bp in the proband,
whereas the control sample showed only the 660 bp product (Fig. 5A). DNA sequencing of
exon 4 of the FTL gene in the proband revealed a novel mutation in one allele of the FTL
gene, c.468_483dupTGGCCCGGAGGCTGGG (Fig. 5B). The position of the mutation was
near to that of previously reported Japanese (Ohta, 2008) and Italian (Storti, 2013) mutation,
c.469_484dupGGCCCGGAGGCTGGGC, shifted one nucleotide to the 5′ of the previously
reported mutation sequence. To confirm the presence of the mutation found in the proband,
the PCR products of the amplification of exons 3 and 4 were subcloned and recombinant
plasmid DNA isolated and sequenced in both directions. Sequence analysis confirmed the
presence of the 16 bp insertion in the mutant allele (Fig. 5B). As a result, the predicted
mutant polypeptide (p.Leu162TrpfsX24) and the previously reported mutant polypeptide
(p.Leu162ArgfsX24) (Ohta, 2008; Storti, 2013) have a different amino acid at codon 162
(tryptophan in p.Leu162TrpfsX24 and arginine in p.Leu162ArgfsX24) but identical
sequence and length of the C-terminus of the mutant protein (Fig. 5C). The mutation was not
observed in the proband’s parents or her brother, who had normal serum ferritin levels and
Nishida et al. Page 4
J Neurol Sci. Author manuscript; available in PMC 2015 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
unremarkable MRI. Genetic analyses for mutations associated with spinocerebellar
degeneration, such as spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8,
SCA10, SCA12, SCA17), and dentatorubral–pallidoluysian atrophy, were negative. No
mutations were observed in the pantothenate kinase 2 (PANK2) gene associated with
pantothenate kinase-associated neurodegeneration (PKAN).
4. DISCUSSION
We report a Japanese female with neuroferritinopathy harboring a novel mutation in exon 4
of the FTL gene. The proband presented by age 42 with chronic headaches, developing
during the next two years progressive orolingual and arm dystonia, dysarthria, cerebellar
ataxia, pyramidal tract signs, and psychiatric symptoms. Previously reported individuals
with neuroferritinopathy show dystonia and dysarthria although our proband did not present
initially with dystonia, she gradually exhibited progressive orolingual and limb dystonia
over several months. It has been previously reported that the clinical presentation of the
disease may be highly variable not only between families but also within a family (Wills,
2002; Chinnery, 2003; Mir, 2005; Chinnery, 2007; Cassidy, 2011; Crompton, 2005; Ory-
Magne, 2009; Vidal, 2011), suggesting that a heterogeneous presentation may be a
characteristic of neuroferritinopathy. Although dystonia and dysarthria are the main
manifestations of this condition, the disease cannot be diagnosed only on the basis of clinical
symptoms alone because many other clinical features such as pyramidal signs, cerebellar
ataxia, dysautonomia, cognitive impairment, and psychiatric symptoms may be observed in
affected individuals.
The MRI findings in patients with neuroferritinopathy change with disease progression
according to clinical stage. In the early clinical stage, hypointense lesions in the basal
ganglia are observed on T2*-weighted images and SWI, particularly in the globus pallidus
and putamen (Lehn, 2012). With disease progression, the T2* signal loss extends to the
dentate nucleus, red nucleus, substantia nigra, thalamus, caudate nucleus, and cerebral
cortex (Ohta, 2012). In later stages, hyperintense lesions in the basal ganglia reflecting
neuronal loss and gliosis due to iron deposition and ferritin accumulation can be seen on T2-
weighted images. In our case, hypointense lesions on T2* images indicative of widespread
abnormal iron deposition were observed in theglobus pallidus, putamen, caudate, thalamus,
red nucleus, dentate nucleus, and motor cortex. In addition, T2-weighted imaging revealed
mild cerebral and cerebellar cortical atrophy and symmetrical hyperintense areas surrounded
by hypointense areas in the bilateral posterior globus pallidus and putamen. The present
individual has not revealed the bilateral large cavities observed in advanced-stage disease.
And interestingly, in our case, brain MRI showed the hypointensity in the basal ganglia on
T2-weighted MRI images before symptom onset (Fig. 1B). A previous study of young
carriers of the c.460InsA mutation (6–36 years old), showed the presence of hypointense
signals on T2*-weighted images indicative of iron deposition (Keogh, 2012), strongly
suggesting that iron deposition may actually begin several decades before the appearance of
clinical symptoms. Coronal T2*-weighted images showed a combination of a hypointense
rim and hyperintense center in the basal ganglia called the “eye of the tiger” sign, which
reflects iron deposition in the basal ganglia on both T2- and T2*-weighted MRI. This sign
has been considered to be pathognomonic of PKAN, but it has also been observed in other
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neurodegenerative diseases such as cortical–basal ganglionic degeneration, multiple system
atrophy, progressive supranuclear palsy, pure akinesia with gait freezing (Erro, 2011), and
neuroferritinopathy (McNeill, 2008). These studies point out a substantial degree of overlap
between neuroferritinopathy and other NBIA diseases in terms of presentation on T2*-
weighted images and SWI. Thus, the diagnosis of neuroferritinopathy may not be made
solely on the basis of neuroimaging. Brain perfusion studies in the proband (IMP-SPECT)
showed asymmetric hypoperfusion of the cerebellum and the basal ganglia with
predominance on the right side. This finding is likely to reflect the laterality of neurological
symptoms.
Low serum ferritin levels were initially reported in individuals with the c.460InsA mutation
(Curtis, 2001); however, low serum ferritin levels are not always observed in individuals
with neuroferritinopathy (Curtis, 2001; Wills, 2002; Mancuso, 2005; Mir, 2005; Chinnery,
2007; Ohta, 2008; Ory-Magne, 2009; Devos, 2009; Ondo, 2010; Storti, 2013). Serum
ferritin levels in our premenopausal female patient were 20 ng/mL (normal range, 5–204 ng/
mL), and thus not found to be significantly decreased compared to normal range.
Interestingly, CSF ferritin levels in our patient (<1.00 ng/mL) were significantly lower than
normal levels in control individuals (6.68 ± 0.93 ng/mL), and also lower than ferritin levels
in patients with restless leg syndrome (below 3.5 to 4.1ng/mL), a disease associated with
lower CSF ferritin levels (Earley, 2000; Mizuno, 2005). Further studies will demonstrate
whether the measurement of CSF ferritin levels could be used as a novel biomarker for
neuroferritinopathy.
Patients carrying the mutation c.469_484dupGGCCCGGAGGCTGGGC have been
described in Japan (Ohta, 2008) and Italy (Storti, 2013). This mutation is similar to the one
presented here, with one nucleotide difference that causes a single amino acid change
between both mutant ferritins at codon 162 (Fig. 5C); however, we have observed
significant degree of variability in the presentation of the disease between the affected
individuals from the Japanese family (tremor was the main characteristic symptom) (Ohta,
2008), the Italian patient (behavioral changes and tremor) (Storti, 2013) and our case. This
difference may not be explained at the protein level, since the general structure of the
spherical protein shell seems to be maintained in mutant ferritin as was seen by X-ray
crystallography (Baraibar, 2010). All known mutations associated with the disease may have
a similar effect: the disruption of the 4-fold pores, making the pores unstable and leaky, and
the gradual aggregation of ferritin and iron into a precipitate mediated by the unraveled and
extended mutant C-termini (reviewed by Muhoberac, 2013). Further research will be needed
to understanding the effect of amino acid variations between mutant C-terminal sequences in
the pathogenic process of the disease and the role of genetic and environmental factors in the
disease.
In conclusion, our findings expand the genetic and phenotypic diversity of
neuroferritinopathy. The observed clinical features of the disease in this family further imply
the importance of testing for FTL mutations in patients with distinctive MRI findings.
Further studies will determine the clinical significance of low levels of CSF ferritin and the
potential value of determining CSF ferritin levels for the diagnosis of the disease.
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Highlights
• We provide novel evidence of the genetic and phenotypic diversity of
neuroferritinopathy
• Discovered a novel FTL mutation associated with neuroferritinopathy
• We presented data on the atypical presentation of the disease
• We propose CSF ferritin levels as a novel biochemical marker for diagnosis
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Figure 1.
A. Pedigree of the family. The square symbols represent males and the circle symbols
represent females. The filled symbol represents the proband. The symbol “/” represents
deceased individuals. The numbers under the symbols represent current age. B. MRI of the
proband at the age of 42, before onset of neurological symptoms.
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Figure 2.
CT and MRI scans of the proband at the age of 44. A. Axial head CT shows symmetrical
hypodense lesions in the basal ganglia, bilaterally. B. T1 weighted axial MRI image shows
symmetrical hypointense areas in the basal ganglia, revealing the degenerative and partially
cystic nature of the lesions. C. T2 weighted axial MRI image showing symmetrical
hyperintense areas encircled by hypointense areas in the bilateral posterior globus pallidus
and putamen. D–H. T2* weighted axial MRI images showing hypointense areas in dentate
nucleus (D), red nucleus (E), globus pallidus, putamen, caudate, thalamus (F, G), and
cerebral cortex (H), suggesting increased deposition of ferritin in multiple nuclei. I. T2*
weighted coronal MRI image showing a hypointense rim and a hyperintense center
reminiscent of the “eye of the tiger” sign in the basal ganglia.
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Figure 3.
Axial susceptibility-weighted images (SWI) show hypointense areas in the globus pallidus,
putamen, caudate, thalamus, red nucleus, dentate nucleus, and motor cortex.
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Figure 4.
123I-iodoamphetamine single photon emission tomography (IMP-SPECT) shows
hypoperfusion in the bilateral cerebellum and right basal ganglia.
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Figure 5.
Genetic analyses of the FTL gene in the proband. A. Analysis of PCR products containing
exons 3 and 4 of the FTL gene by agarose gels show that the proband (P) has an additional
band (676 bp) in addition to the normal amplification product of 660 bp observed in control
individuals. B. Direct sequencing of genomic DNA from the proband (top) and cloned DNA
containing the mutant allele (bottom) clearly showing the beginning (thymine) of the 16-
nucleotide duplication (c.468_483dupTGGCCCGGAGGCTGGG). Wild-type nucleotide
sequence is indicated on top and the duplicated sequence on bottom. C. Wild-type sequence
(top) and mutant sequences (bottom) of the FTL gene showing the 16-bp duplication. The
duplicated nucleotide sequences are underlined. The p.Leu162ArgfsX24 was previously
reported in Japanese (Ohta, 2008) and Italian (Storti, 2013) affected individuals. The
predicted C-terminal amino acid sequences are indicated. Amino acid 162 is in bold.
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